Related Experiment Video

Updated: Jan 31, 2026

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
14:10

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

16.5K

MiR-650 inhibits the progression of glioma by targeting FAM83F

L Xu1, Q-W Yu, S-Q Fang

  • 1Department of Neurosurgery, Central People's Hospital of Zhanjiang, Zhanjiang, China. xuliniu@126.com.

European Review for Medical and Pharmacological Sciences
|December 18, 2018
PubMed
Abstract

Insights

MicroRNA-650 (miR-650) is downregulated in glioma and inhibits tumor cell proliferation by targeting FAM83F. Low miR-650 expression promotes glioma growth by upregulating FAM83F.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Glioma is a primary brain tumor with complex molecular underpinnings.
  • MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
  • Identifying novel molecular targets is essential for effective glioma therapy.

Purpose of the Study:

  • To investigate the role of miR-650 in glioma proliferation.
  • To determine if miR-650 regulates FAM83F expression.
  • To explore the therapeutic potential of miR-650 in glioma.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) for gene expression analysis.
  • Cell proliferation assays (CCK-8, EDU) to assess cell viability.
  • Luciferase reporter gene assay and rescue experiments to confirm molecular interactions.

Main Results:

  • MiR-650 expression was significantly decreased in glioma tissues and cell lines.
  • FAM83F expression was inversely correlated with miR-650 levels.
  • Overexpression of miR-650 inhibited glioma cell proliferation by targeting FAM83F.

Conclusions:

  • MiR-650 acts as a tumor suppressor in glioma.
  • Downregulation of miR-650 contributes to glioma progression.
  • Targeting FAM83F by miR-650 presents a potential therapeutic strategy for glioma.

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

4.0K
Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells09:58

Preparation and In Vitro Characterization of Magnetized miR-modified Endothelial Cells

Published on: May 2, 2017

8.1K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K